New drug trial aims to tame rogue immune system in rare disorder
NCT ID NCT06897358
Summary
This study is testing an oral drug called leniolisib in about 20 people with Common Variable Immunodeficiency (CVID) who also have specific immune system overactivity problems. The main goal is to see if the drug is safe and well-tolerated when taken for 6 months at increasing doses. Researchers will also look for early signs that the drug might help reduce issues like enlarged lymph nodes, spleen problems, low blood counts, or lung inflammation caused by the immune system.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COMMON VARIABLE IMMUNODEFICIENCY (CVID) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's Hospital Colorado
Aurora, Colorado, 80045, United States
-
IIS La Fe
Valencia, Spain
-
Lahey Hospital & Medical Center
Burlington, Massachusetts, 01805, United States
-
Leeds Teaching Hospital NHS Trust
Leeds, United Kingdom
-
Mount Sinai Hospital
New York, New York, 10029, United States
-
National Institute of Health
Bethesda, Maryland, 20892, United States
-
Texas Children's Hospital
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.